Detecting Recurrent Prostate Cancer With 11C-choline Positron Emission Tomography

NCT02531672 · Status: NO_LONGER_AVAILABLE · Type: EXPANDED_ACCESS

Last updated 2020-06-05

No results posted yet for this study

Summary

The purpose of this study is to use a new imaging drug called 11C-choline that is used with a PET/CT scan to see prostate cancer when it cannot be seen well on other scans, such as bone scans, CT or MRI.

Conditions

Interventions

DRUG

11C-choline

DEVICE

PET/CT Scan

Sponsors & Collaborators

Principal Investigators

  • Heiko Schӧder, MD · Memorial Sloan Kettering Cancer Center

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Countries

  • United States

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02531672 on ClinicalTrials.gov